Sugi Predict

Sugi Predict / Compounds / SCHEMBL708366

SCHEMBL708366

SCHEMBL708366

COc1cc(OC)cc(C(=O)N(C)OC)c1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CLK1 P49759 1/20 0.47
▸ DYRK1A Q13627 1/20 0.47
▸ DYRK1B Q9Y463 1/20 0.47
▸ ABCG2 Q9UNQ0 1/20 0.47
▸ ALDH1A1 P00352 2/20 0.44
▸ MLYCD O95822 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ RXRA P19793 1/20 0.42
▸ CES2 O00748 1/20 0.41
▸ CES1 P23141 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ CYP1A1 P04798 1/20 0.40
▸ CYP1B1 Q16678 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5777011 0.88 CLK1 (0.42) CLK1DYRK1ADYRK1BABCG2ALDH1A1
SCHEMBL17204872 0.88 CLK1 (0.42) CLK1DYRK1ADYRK1BABCG2ALDH1A1
SCHEMBL1188757 0.85 MLYCD (0.43) CLK1DYRK1ADYRK1BABCG2ALDH1A1
SCHEMBL16729520 0.84 CLK1 (0.40) CLK1DYRK1ADYRK1BABCG2MLYCD
SCHEMBL1189827 0.84 MLYCD (0.49) CLK1DYRK1ADYRK1BMLYCDRXRA
SCHEMBL31032795 0.84 CLK1 (0.40) CLK1DYRK1ADYRK1BABCG2MLYCD
SCHEMBL1162304 0.83 ALDH1A1 (0.50) ABCG2ALDH1A1KDM4EGAARXRA
SCHEMBL307622 0.82 CES2 (0.62) CLK1DYRK1ADYRK1BABCG2KDM4E
SCHEMBL1816644 0.82 KMT2A (0.41) CLK1DYRK1ADYRK1BALDH1A1MLYCD
SCHEMBL1436162 0.82 ALDH1A1 (0.46) ABCG2ALDH1A1KDM4EGAARXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114773326-A Method for synthesizing natural product (+) -Machaeriols B 南京工业大学 2022-07-22 — — CN claimed
CN-114773326-B Synthesis method of natural product (+) -Machaeriols B 南京工业大学 2025-07-04 — — CN disclosed
EP-3722276-B1 PROCESS FOR THE PRODUCTION OF PURIFIED CANNABIDIOL PURISYS LLC (US) 2025-01-08 — — EP disclosed
WO-2022159506-A1 DEUTERATED CANNABIDIOL COMPOUNDS MERIT THERAPEUTICS, INC. (US) 2022-07-28 — — WO disclosed
CN-114773326-A Method for synthesizing natural product (+) -Machaeriols B 南京工业大学 2022-07-22 — — CN disclosed
CN-114773326-A Method for synthesizing natural product (+) -Machaeriols B 南京工业大学 2022-07-22 — — CN disclosed
US-20210061781-A1 PROCESS FOR THE PRODUCTION OF CANNABIDIOL AND DELTA-9-TETRAHYDROCANNABINOL NORAMCO, INC. 2021-03-04 — — US disclosed
US-20210061781-A1 PROCESS FOR THE PRODUCTION OF CANNABIDIOL AND DELTA-9-TETRAHYDROCANNABINOL NORAMCO, INC. 2021-03-04 — — US disclosed
US-10844035-B2 Process for the production of cannabidiol and delta-9-tetrahydrocannabinol PURISYS LLC (US) 2020-11-24 — — US disclosed
US-10844035-B2 Process for the production of cannabidiol and delta-9-tetrahydrocannabinol PURISYS LLC (US) 2020-11-24 — — US disclosed
US-20060148830-A1 Lpa receptor antagonist ONO PHARMACEUTICAL CO., LTD. 2006-07-06 — — US disclosed
US-20060135577-A1 Remedy for chronic disease ONO PHARMACEUTICAL CO., LTD. (JP) 2006-06-22 — — US disclosed
EP-1469842-A4 BICYCLIC CB2 CANNABINOID RECEPTOR LIGANDS PHARMOS CORP (US) 2006-04-26 — — EP disclosed
WO-2005103033-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2005-11-03 — — WO disclosed
EP-1553075-A1 LPA RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2005-07-13 — — EP disclosed
EP-1550461-A1 REMEDY FOR CHRONIC DISEASE ONO PHARMACEUTICAL CO., LTD. (JP) 2005-07-06 — — EP disclosed
US-20050020544-A1 Bicyclic CB2 cannabinoid receptor ligands PHARMOS CORPORATION 2005-01-27 — — US disclosed
EP-1469842-A2 BICYCLIC CB2 CANNABINOID RECEPTOR LIGANDS PHARMOS CORPORATION (US) 2004-10-27 — — EP disclosed
WO-2003063758-A2 BICYCLIC CB2 CANNABINOID RECEPTOR LIGANDS PHARMOS CORPORATION (US) 2003-08-07 — — WO disclosed
WO-2003064359-A1 BICYCLIC CB2 CANNABINOID RECEPTOR LIGANDS PHARMOS CORPORATION (US) 2003-08-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10844035-B2 Process for the production of cannabidiol and delta-9-tetrahydrocannabinol SQLE, CNR2, DAGLA CLK1 598/4885DYRK1A 281/4885DYRK1B 212/4885
US-20050020544-A1 Bicyclic CB2 cannabinoid receptor ligands CNR1, CNR2, CHRNE CLK1 2386/4885DYRK1A 3990/4885DYRK1B 4369/4885
US-20210061781-A1 PROCESS FOR THE PRODUCTION OF CANNABIDIOL AND DELTA-9-TETRAHYDROCANNABINOL CNR2, HDHD5, DAGLA CLK1 331/4885DYRK1A 117/4885DYRK1B 98/4885
US-20060135577-A1 Remedy for chronic disease EDNRA, EDNRB, LPAR2 CLK1 3139/4885DYRK1A 1168/4885DYRK1B 1239/4885
US-20060148830-A1 Lpa receptor antagonist LPAR1, LPAR2, LPAR4 CLK1 3351/4885DYRK1A 4663/4885DYRK1B 4596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.